ORTHOCON® estimates that over 3.5 million patients undergoing surgeries in the United States and Europe each year could benefit from the intraoperative use of HEMASORB.

New Company Abyrx, Inc. Acquires Substantially All of the Assets of Orthocon and DRG
April 24, 2013 - Click to Download

ORTHOCON® Announces Uninterrupted Availability of HEMASORB Resorbable Hemostatic Bone Putty
August 23, 2012 - Click to Download